59

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group-4 randomized trial.

Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L.

Eur Urol. 2012

SPCG-4

Abstract

58

Long-term quality of life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomized trial.

Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Bill-Axelson A; SPCG-4 investigators.

Lancet Oncol 2011

SPCG-4

Abstract

57

Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.

Solberg A, Widmark A, Tasdemir I, Ahlgren A, Angelsen A.

Scand J Urol Nephrol. 2011

SPCG-7 Biopsy study

Abstract

56

Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial

Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, Widmark A, Angelsen A

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):55-61

SPCG-7 Biopsy study

Abstract

55

Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).

Andersson SO, Andren O, Lyth J, Stark JR, Henriksson M, Adami HO, Carlsson P, Johansson JE.

Scand J Urol Nephrol. 2011

SPCG-4

Abstract

54

Inguinal hernia after radical prostatectomy for prostate cancer: results from a randomized setting and a nonrandomized setting

Stranne J, Johansson E, Nilsson A, Bill-Axelsson A, Carlsson S, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Wiklund NP, Steineck G

Eur Urol. 2010

SPCG-4

Abstract

53

Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer

Steinsvik EA, Fosså SD, Axcrona K, Fransson P, Widmark A, Dahl AA

J Urol. 2010

SPCG-7/FUO3

Abstract

52

Validation of the intestinal part of the prostate cancer questionnaire «QUFW94»: psychometric properties, responsiveness, and content validity

Reidunsdatter RJ, Lund JA, Fransson P, Widmark A, Fosså SD, Kaasa S

Int J Radiat Oncol Biol Phys. 2010

SPCG-7/FUO3

Abstract

51

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A

Lancet Oncol. 2009

SPCG-7/FUO3

Abstract

50

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: The randomized Scandinavian Prostate Cancer Group study number 4

Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson J-E, Steineck G

Eur Urol. 2009

SPCG-4

Abstract